Valuation: Clene Inc.

Market Cap 6.4Cr 5.56Cr 5.16Cr 4.76Cr 8.97Cr 611.18Cr 9.13Cr 61Cr 24Cr 303.55Cr 24Cr 24Cr 1.02TCr P/E 2026 *
-2.82x
P/E 2027 * -3.42x
Enterprise Value 5.06Cr 4.4Cr 4.08Cr 3.77Cr 7.09Cr 483.26Cr 7.22Cr 48Cr 19Cr 240.01Cr 19Cr 19Cr 807.14Cr EV / Sales 2026 *
244x
EV / Sales 2027 * 1.8x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+6.78%
1 week-8.03%
Current month-18.12%
1 month-18.12%
3 months-18.18%
6 months+23.23%
Current year-14.14%
1 week 4.63
Extreme 4.63
5.47
1 month 4.63
Extreme 4.63
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.3
Extreme 3.3
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
04/05/26 Sell -72,884 0.6188%
19/02/26 Free

Founder

3,306 0.0281%
19/02/26 Free

Director

3,168 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
+6.78%-8.03%+44.41%-66.40% 6.03Cr
-0.81%-0.33%+27.15%+81.12% 5.56TCr
-3.74%-6.32%+42.70%+64.45% 5.52TCr
-0.11%+0.86%-15.63%-13.56% 2.35TCr
-1.58%-5.51%-3.51%+375.36% 2.24TCr
+2.54%-0.92%+20.31%-12.15% 2.06TCr
-1.23%-3.15%+26.00%-31.88% 1.74TCr
+1.79%-4.79%+17.64%+547.78% 1.52TCr
+1.16%+0.58%+51.87%+181.96% 1.39TCr
-5.09%-10.87%+153.11%+272.20% 1.37TCr
Average -0.04%-3.28%+36.41%+139.89% 2.38TCr
Weighted average by Cap. -1.21%-0.46%+31.10%+125.87%

Financials

2026 *2027 *
Net sales 2L 2L 2L 2L 3L 1.98Cr 3L 19.81L 8L 98.34L 8L 8L 3.31Cr 2.36Cr 2.05Cr 1.91Cr 1.76Cr 3.31Cr 225.73Cr 3.37Cr 23Cr 8.84Cr 112.11Cr 8.88Cr 8.68Cr 377.01Cr
Net income -2.51Cr -2.18Cr -2.02Cr -1.87Cr -3.52Cr -239.57Cr -3.58Cr -24Cr -9.38Cr -118.98Cr -9.42Cr -9.22Cr -400.12Cr -2.75Cr -2.39Cr -2.22Cr -2.05Cr -3.86Cr -263Cr -3.93Cr -26Cr -10Cr -130.62Cr -10Cr -10Cr -439.26Cr
Net Debt -1.34Cr -1.16Cr -1.08Cr -99.68L -1.88Cr -127.93Cr -1.91Cr -13Cr -5.01Cr -64Cr -5.03Cr -4.92Cr -213.67Cr -2.14Cr -1.86Cr -1.73Cr -1.59Cr -3Cr -204.3Cr -3.05Cr -20Cr -8Cr -101.47Cr -8.04Cr -7.86Cr -341.23Cr
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
30/26/30 $5.040 +6.78% 37,349
29/26/29 $4.720 -5.41% 1,40,746
28/26/28 $4.990 -8.61% 93,043
27/26/27 $5.460 +1.30% 28,258
24/26/24 $5.390 -1.64% 48,257
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.010USD
Average target price
32.20USD
Spread / Average Target
+542.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock